Urology Annals (Jan 2021)

High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center

  • Marilyne Daher,
  • Talar Telvizian,
  • Christelle Dagher,
  • Zahi Abdul-Sater,
  • Sarah Abdel Massih,
  • Alissar EL Chediak,
  • Maya Charafeddine,
  • Mohammed Shahait,
  • Raafat Alameddine,
  • Sally Temraz,
  • Fady Geara,
  • Bassem Youssef,
  • Albert El Hajj,
  • Rami Nasr,
  • Wassim Wazzan,
  • Muhammad Bulbul,
  • Raja Khauli,
  • Ali Shamseddine,
  • Deborah Mukherji

DOI
https://doi.org/10.4103/UA.UA_47_20
Journal volume & issue
Vol. 13, no. 4
pp. 418 – 423

Abstract

Read online

Objectives: Prostate cancer incidence is increasing in the Middle East (ME); however, the data of stage at the diagnosis and treatment outcomes are lacking. In developed countries, the incidence of de novo metastatic prostate cancer ranges between 4% and 14%. We hypothesized that the rates of presentation with advanced disease are significantly higher in the ME based on clinical observation. This study aims to examine the stage at the presentation of patients with prostate cancer at a large tertiary center in the ME. Methods: After Institutional Review Board approval, we identified the patients diagnosed with prostate adenocarcinoma and presented to a tertiary care center between January 2010 and July 2015. Clinical, demographic, and pathological characteristics were abstracted. Patients with advanced disease were stratified according to tumor volume based on definitions from practice changing clinical trials. Descriptive and Kaplan–Meier survival analysis was used. Results: A total of 559 patients were identified, with a median age at the diagnosis of 65 years and an age range of 39–94 years. Median prostate-specific antigen (PSA) at the presentation was 10 ng/ml, and almost a quarter of the men (23%) presented with metastatic disease. The most common site of metastasis was the bone (34/89, 38%). High-volume metastasis was present in 30.3%, 9%, and 5.2% of the cohort based on STAMPEDE, CHAARTED, and LATITUDE trial criteria, respectively. Conclusion: This is the first report showing the high proportion of men from ME presenting with de novo metastasis. This could be due to many factors, including the highly variable access to specialist multidisciplinary management, lack of awareness, and lack of PSA screening in the region. There is a clear need to raise the awareness about prostate cancer screening and early detection and to address the rising burden of advanced prostate cancer affecting men in the ME region.

Keywords